PARP inhibitor for Neoadjuvant therapy in HER2-negative breast cancer: a systematic review and meta-analysis of efficacy and safety

Xiaomeng Jia,Kainan Wang,Qiping Zhuo,Zuowei Zhao,Man Li

DOI: https://doi.org/10.1016/j.clbc.2024.02.020

IF: 3.078

2024-03-04

Clinical Breast Cancer

Abstract:Background PARPi 1 is approved for HER2-negative advanced breast cancer with BRCA1/2 mutation. In recent years, many studies have explored the application of PARPi in neoadjuvant therapy, but failed to reach a unified conclusion. Materials and Methods PubMed, Clinicaltrials.gov, Cochrane CENTRAL, Embase and key oncological meetings for trials were searched for studies reporting neoadjuvant regimen with PARPi in HER2-negative breast cancer. pCR 2 , RCB 3 , BCSR 4 , Clinical response and adverse events were extracted and pooled in a meta-analysis using the Mantel Haenszel random/fixed effects model. Subgroup analyses of pCR were conducted according to BRCA1/2 status, HR 5 status. Results Five studies (N=1223) were included, the addition of PARPi to neoadjuvant regiman significantly increased pCR rates(HR 1.45, 95%CI 1.09-1.92, P=0.01, I 2 =86%). In subgroup analysis, the addition of PARPi increased the pCR rate both in HR positive(n= 383) and HR negative(n=431) subgroup, which showed a dominant effect of PARPi regardless of HR status(HR 2.07, 95%CI 1.33-3.23, P=0.001, I 2 =0%; HR 1.85, 95%CI 1.39-2.26, P<0.0001, I 2 =0%, respectively). However, when we performed a subgroup analysis based on the status of BRCA1/2 , no further benefit for PARPi was found. Adverse reactions were generally tolerable. For other outcome indexes, including RCB, clinical response, BCSR, PARPi did not show a clinical benefit. Conclusion Regardless of BRCA1/2 status, PARPi in neoadjuvant therapy can improve pCR rate of HER2-negative breast cancer, especially HR positive patients. Thus, we should have perform larger randomized trials and provide a stronger evidence-based basis.

oncology